This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Slagsvold, T. Articles by Saatcioglu, F. Search for Related Content PubMed PubMed Citation Articles by Slagsvold, T. Articles by Saatcioglu, F.

Mutational Analysis of the Androgen Receptor AF-2 (Activation Function 2) Core Domain Reveals Functional and Mechanistic Differences of Conserved Residues Compared with Other Nuclear Receptors

Biotechnology Centre of Oslo (T.S., I.K., T.B., F.S.), and Department of Biochemistry (T.S.), Department of Biology (I.K., T.B.), and Institute for Clinical Medicine (F.S.) University of Oslo 0349 Oslo, Norway
Department of Physiology (J.P.) Institute of Biomedicine University of Helsinki FIN-00014 Helsinki, Finland

A short C-terminal sequence that forms the core of the activation function-2 (AF-2) domain is conserved in members of the nuclear receptor superfamily and is required for their normal biological function. Despite a high degree of sequence similarity, there are differences in the context and structure of AF-2 in different nuclear receptors. To gain deeper insight into these differences, we carried out an extensive mutational analysis of the AF-2 core in the androgen receptor (AR) and compared the changes in transcriptional activity with similar mutations that have previously been generated in other nuclear receptors. Mutagenesis of Met894 to Asp resulted in substantial decreases in both DNA and ligand binding activities and, consequently, a significant drop in ligand-dependent transcriptional activation. In contrast, substitution of Met894 with Ala did not affect DNA or hormone binding, and the transactivation potential was comparable to that of wild-type AR. Mutagenesis of Glu897 either with Val or Ala significantly impaired ligand-dependent activation that was not due to changes in DNA or ligand binding. There are both similarities and distinct differences between these findings compared with previous mutagenesis studies of the corresponding residues in other nuclear receptors. All mutants efficiently interfered with AP-1 activity, indicating that ligand-dependent activation of transcription and interference with AP-1 activity are separable functions in AR. For the Glu897 substitutions, the decrease in ligand-dependent transactivation could partially be reversed by overexpression of GRIP1 (GR-interacting protein 1) or CBP, putative coactivators for AR. However, there was no correlation between ligand-dependent in vitro or in vivo association with coactivators and the ability of the mutants to support ligand-dependent transactivation. This is in contrast to similar mutations in other nuclear receptors that lose interactions with putative coactivators concomitant with their loss of transcriptional activity. However, the Glu897 mutations disrupted the intramolecular interaction between the N-terminal domain and the ligand-binding domain of AR that was recently suggested to be required for normal AR function. We conclude that residues in the AF-2 core domain of AR make distinctly different contributions to its transcriptional activities compared with those of other nuclear receptors studied to date.

This article has been cited by other articles:

				H. Zong, Y. Chi, Y. Wang, Y. Yang, L. Zhang, H. Chen, J. Jiang, Z. Li, Y. Hong, H. Wang, et al. Cyclin D3/CDK11p58 Complex Is Involved in the Repression of Androgen Receptor Mol. Cell. Biol., October 15, 2007; 27(20): 7125 - 7142. [Abstract] [Full Text] [PDF]

				T. I. Klokk, P. Kurys, C. Elbi, A. K. Nagaich, A. Hendarwanto, T. Slagsvold, C.-Y. Chang, G. L. Hager, and F. Saatcioglu Ligand-Specific Dynamics of the Androgen Receptor at Its Response Element in Living Cells Mol. Cell. Biol., March 1, 2007; 27(5): 1823 - 1843. [Abstract] [Full Text] [PDF]

				S. M. Dehm and D. J. Tindall Ligand-independent Androgen Receptor Activity Is Activation Function-2-independent and Resistant to Antiandrogens in Androgen Refractory Prostate Cancer Cells J. Biol. Chem., September 22, 2006; 281(38): 27882 - 27893. [Abstract] [Full Text] [PDF]

				G. Chen, M. Nomura, H. Morinaga, E. Matsubara, T. Okabe, K. Goto, T. Yanase, H. Zheng, J. Lu, and H. Nawata Modulation of Androgen Receptor Transactivation by FoxH1: A NEWLY IDENTIFIED ANDROGEN RECEPTOR COREPRESSOR J. Biol. Chem., October 28, 2005; 280(43): 36355 - 36363. [Abstract] [Full Text] [PDF]

				E. Estebanez-Perpina, J. M. R. Moore, E. Mar, E. Delgado-Rodrigues, P. Nguyen, J. D. Baxter, B. M. Buehrer, P. Webb, R. J. Fletterick, and R. K. Guy The Molecular Mechanisms of Coactivator Utilization in Ligand-dependent Transactivation by the Androgen Receptor J. Biol. Chem., March 4, 2005; 280(9): 8060 - 8068. [Abstract] [Full Text] [PDF]

				A. Umar, C. A. Berrevoets, N. M. Van, M. van Leeuwen, M. Verbiest, W. J. Kleijer, D. Dooijes, J. A. Grootegoed, S. L. S. Drop, and A. O. Brinkmann Functional Analysis of a Novel Androgen Receptor Mutation, Q902K, in an Individual with Partial Androgen Insensitivity J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 507 - 515. [Abstract] [Full Text] [PDF]

				S. Shah, A. Hecht, R. Pestell, and S. W. Byers Trans-repression of {beta}-Catenin Activity by Nuclear Receptors J. Biol. Chem., November 28, 2003; 278(48): 48137 - 48145. [Abstract] [Full Text] [PDF]

				V. Christiaens, C. L. Bevan, L. Callewaert, A. Haelens, G. Verrijdt, W. Rombauts, and F. Claessens Characterization of the Two Coactivator-interacting Surfaces of the Androgen Receptor and Their Relative Role in Transcriptional Control* J. Biol. Chem., December 13, 2002; 277(51): 49230 - 49237. [Abstract] [Full Text] [PDF]

				B. Borud, T. Hoang, M. Bakke, A. L. Jacob, J. Lund, and G. Mellgren The Nuclear Receptor Coactivators p300/CBP/Cointegrator-Associated Protein (p/CIP) and Transcription Intermediary Factor 2 (TIF2) Differentially Regulate PKA-Stimulated Transcriptional Activity of Steroidogenic Factor 1 Mol. Endocrinol., April 1, 2002; 16(4): 757 - 773. [Abstract] [Full Text] [PDF]

				E. Holter, N. Kotaja, S. Makela, L. Strauss, S. Kietz, O. A. Janne, J.-A. Gustafsson, J. J. Palvimo, and E. Treuter Inhibition of Androgen Receptor (AR) Function by the Reproductive Orphan Nuclear Receptor DAX-1 Mol. Endocrinol., March 1, 2002; 16(3): 515 - 528. [Abstract] [Full Text] [PDF]

				M. B. Martin, H. J. Voeller, E. P. Gelmann, J. Lu, E.-G. Stoica, E. J. Hebert, R. Reiter, B. Singh, M. Danielsen, E. Pentecost, et al. Role of Cadmium in the Regulation of AR Gene Expression and Activity Endocrinology, January 1, 2002; 143(1): 263 - 275. [Abstract] [Full Text] [PDF]

				J. Thompson, F. Saatcioglu, O. A. Janne, and J. J. Palvimo Disrupted Amino- and Carboxyl-Terminal Interactions of the Androgen Receptor Are Linked to Androgen Insensitivity Mol. Endocrinol., June 1, 2001; 15(6): 923 - 935. [Abstract] [Full Text] [PDF]

				T. Slagsvold, I. Kraus, K. Fronsdal, and F. Saatcioglu DNA Binding-independent Transcriptional Activation by the Androgen Receptor through Triggering of Coactivators J. Biol. Chem., August 10, 2001; 276(33): 31030 - 31036. [Abstract] [Full Text] [PDF]